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 ABSTRACT 
 Background/aims  Treatment wi th intralesional 
triamcinolone/betamethasone is recommended for 
infantile sight-threatening periocular haemangiomas. 
This study investigates the endocrine and weight 
changes in 15 infants undergoing therapy over 12 years. 
 Methods  15 infants, median age 19 weeks (range 
10–56) receiving intra/perilesional triamcinolone/
betamethasone underwent serial measurement of weight, 
early morning serum cortisol and adrenocorticotropic 
hormone (ACTH) before and after injection. 
 Results  Cortisol fell from a median (range) of 383 
(112–594) to 28 (<10–506) nmol/l (p=0.005) and ACTH 
from 26 (14–134) to 9 (5–20) ng/l (p=0.05) from before 
injection to 4 weeks after treatment. Prolonged adrenal 
suppression occurred in 13 out of 15 cases with time to 
recovery being 19.5 (4–65) weeks. Failure to gain weight 
appropriately was observed in 14 infants but recovered 
once normal adrenal function was re-established. 
 Conclusion  Prolonged adrenal suppression following 
triamcinolone/betamethasone injection for periocular 
haemangiomas is common and associated with faltering 
weight gain. 
 INTRODUCTION 
 Haemangiomas are the most common benign 
tumour of infancy, the estimated prevalence 
in neonates being 1–3% with 70–90% resolv-
ing spontaneously by 7 years of age. Periocular 
haemangiomas have a number of potential com-
plications including amblyopia, astigmatism, 
strabismus, proptosis and optic atrophy. If sight-
threatening complications are envisaged, interven-
tion with corticosteroids should be considered.  1  
Until recently intralesional injection with triamci-
nolone/betamethasone was considered the treat-
ment of choice to induce resolution ( ﬁ gure 1A,B ). 
However, propranolol may offer a new treatment 
modality for the future.  2  
 Previous observations of reversible adrenal 
suppression and poor weight gain following tri-
amcinolone/betamethasone therapy  3  led to the 
instigation of a treatment protocol (see Methods 
section for details), whereby all children receiv-
ing such therapy ha d adrenal function assessed 
before and after treatment. Where adrenal sup-
pression occurred, treatment with hydrocortisone 
was started until recovery of adrenal function. 
This paper describes the outcomes for a cohort of 
children treated under this joint care (ophthalmol-
ogy and paediatric endocrinology) protocol from 
1996 to 2007. The systematic documentation of 
adrenal function and weight in these children has 
conﬁ rmed the clinically signiﬁ cant consequences 
of this treatment on adrenal function and weight 
gain and has implications for the management of 
children with sight-threatening haemangiomas. 
Propranolol may offer a less toxic treatment 
modality but has yet to undergo rigorous trials.  2  
 METHODS 
 All children treated with triamcinolone/betame-
thasone for periocular haemangiomas in a single 
teaching hospital from 1996 to 2007 inclusive 
were identiﬁ ed. The dose of triamcinolone varied 
between 20 and 40 mg, whereas betamethasone 
was given in a ﬁ xed dose of 2 mg. All children 
received a mixture of both triamcinolone and 
betamethasone simultaneously. 
 Morning serum cortisol concentrations were 
measured before injection (ADVIA Centaur 
Cortisol; Siemens Healthcare Diagnostics, 
Deerﬁ eld, Illinois, US A) and 4-weekly thereafter. 
Children with an early morning serum cortisol 
concentration of <120 nmol/l (the lower limit of 
reference range for the assay) 4 weeks after injec-
tion were considered to have adrenal suppression 
and hydrocortisone treatment was instigated 
(10 mg/m  2  /day in two or three divided doses) with 
a ‘steroid card’ provided to alert other healthcare 
professionals. Early morning serum cortisol and 
adrenocorticotropic hormone (ACTH) concentra-
tions (Immulite; Siemens He althcare Diagnostics) 
were remeasured every 4–6 weeks on hydro-
cortisone treatment following omission of the 
previous evening and morning doses of hydrocor-
tisone. Testing continued until recovery of basal 
adrenal function was conﬁ rmed (early morn-
ing serum cortisol concentration >120 nmol/l). 
Regular hydrocortisone therapy was then stopped 
and a Synacthen test performed to evaluate adre-
nal responsiveness. A normal Synacthen response 
was taken as a baseline cortisol concentration 
>120 nmol/l with a peak response >550 nmol/l 
and/or a doubling of the baseline value. 
 Weight was measured at each visit and results 
converted to SD scores (SDS) using 1990 British 
reference data. This study was considered an 
audit of service provision and therefore ethics 
consent was not considered necessary. Statistical 
comparisons were performed using non-paramet-
ric analysis. 
 RESULTS 
 Fifteen infants (three boys, 12 girls) received treat-
ment between 1996 and 2007. The median age 
at injection was 19 (range 10–56) weeks. Seven 
infants received a second dose of triamcinolone/
betamethasone due to inadequate resolution of 
the haemangioma at varying intervals. 
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 Thirteen of 15 patients sustained adrenal suppression 4 
weeks following triamcinolone administration (cortisol <120 
nmol/l). There was a fall in serum cortisol concentration from 
a median (range) of 383 (112–594) nmol/l before treatment 
(n=13) to 28 (<10–506) nmol/l (p=<0.005) 4 weeks after injec-
tion (n=15). Likewise, the median (range) ACTH concentration 
fell from 26 (14–134) ng/l (n=10) to 9 (5–20) ng/l (n=11) (p<0.05) 
over the same period. The time from ﬁ rst injection of triam-
cinolone/betamethasone to basal adrenal recovery/resolution 
for all 15 infants varied markedly from 4 to 65 weeks (median 
(IQR) 19.5 (8–42) weeks) but was signiﬁ cantly longer in the 
seven infants requiring a second injection (median (range) 
time to adrenal recovery for infants receiving one or two tri-
amcinolone/betamethasone injections, respectively, 8 (4–35) 
and 41 (15–65) weeks; p=0.017).  Figure 2 shows the time to 
recovery of adrenal function for all 15 infants. Synacthen tests 
performed after a normal basal cortisol were all normal. 
 Failure to gain weight appropriately following the steroid 
injection was demonstrated in 14 of 15 children. A signiﬁ cant 
fall in weight SDS was observed 4 and 8 weeks after the steroid 
injection (median (range) weight SDS at injection, 4 weeks and 
8 weeks, respectively, −0.08 (−2.27 to 2.16), −0.67 (−2.60 to 
1.55) and −0.82 (−3.09 to 1.65); p<0.05). However, by the time 
of basal cortisol recovery and normal Synacthen response, 
there was no signiﬁ cant difference in the weight SDS com-
pared to before triamcinolone treatment (−0.63 (−3.72 to 1.65) 
and 0.15 (−3.72 to 1.33), respectively) demonstrating catch-u p 
growth. Furthermore, the effect of triamcinolone/betametha-
sone on adrenal suppression and/or weight gain did not appear 
to be dose-dependent. Although some infants receiving two 
injections took longer to recover adrenal function, there was 
no signiﬁ cant association between the total dose of triamcino-
lone/betamethasone received and time to recovery. 
 DISCUSSION 
 This retrospective analysis of systematic monitoring of adre-
nal function demonstrates prolonged adrenal suppression in 13 
of 15 patients undergoing intralesional injection of a triamci-
nolone/betamethasone mixture and demonstrates this to be a 
common and potentially serious side-effect with two children 
sustaining adrenal suppression for more than a year. 
 Previously, Goyal  et al  3  speculated that the initial release of 
glucocorticoids into the circulation led to acute adrenal suppres-
sion. The clinical concern is that continued systemic absorp-
tion of steroids from the injection site would then decline at an 
unknown rate until a point when circulating glucocorticoids 
would be insufﬁ cient to prevent an adrenal crisis occurring 
during intercurrent illness given co-existent iatrogenic adrenal 
failure. It is not easy clinically to judge when circulating triam-
cinolone concentrations are insufﬁ cient to prevent an adrenal 
crisis or when full recovery of the hypothalamic-pituitary-
adrenal axis has occurred. 
 Figure 1  (A) Patient before and (B) after treatment with an intralesional triamcinolone/betamethasone mixture. 
A B
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 Our case series has also demonstrated a signiﬁ cant slow-
ing in weight gain following triamcinolone/betamethasone 
injection. This clinical picture is not consistent with the well-
known Cushingoid phenotype associated with high-dose 
glucocorticoid intake. As well as increasing adiposity, glu-
cocorticoids inhibit protein synthesis and stimulate protein 
degradation, important factors in the development of muscle 
atrophy, a characteristic feature of Cushing’s syndrome.  4  
One possible explanation for the phenotype observed in this 
study is that the protein catabolic effects of the exogenous 
steroid outweigh the increase in fat mass that co-exists in 
the presence of iatrogenic Cushing’s syndrome. Supportive 
evidence for this explanation is provided by detailed body 
composition changes in one patient which showed a reduc-
tion in fat-free mass and an increase in fat mass during 
the ﬁ rst 50 days following triamcinolone/betamethasone 
administration.  3  
 There is growing evidence that propranolol, a non-
 selective β-blocker, may offer an alternative treatment to 
 corticosteroids.  2    5  Currently this is an off-label indication 
and parents have to be well informed and give their assent. 
Propranolol has a well documented side-effect proﬁ le from its 
use in cardiovascular disease, although evidence for its effective-
ness in treating haemangiomas only comes from case reports. 
Although this novel therapy should be exposed to more rigor-
ous study, anecdotal evidence suggests that it is already creep-
ing into clinical practice and it seems likely that this treatment 
modality will supercede corticosteroid therapy. 
 In conclusion, our retrospective study yields some important 
ﬁ ndings and provides some guidance for managing infants 
receiving intralesional triamcinolone/betamethasone for peri-
ocular haemangiomas. The potentially life-threatening nature 
of an adrenal crisis necessitates the development of a dialogue 
and sharing of care between staff working in ophthalmology 
and endocrinology departments. Although propranolol may 
supercede the use of corticosteroid therapy for periocular hae-
mangiomas, continued vigilance will be required for adverse 
effects. 
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 Figure 2  Normal adrenal function curve demonstrating the time frame from injection of triamcinolone/betamethasone to recovery of adrenal 
function (basal cortisol >120 nmol/l) for all 15 infants. 
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